Anatara Lifesciences Ltd (ASX:ANR)
0.0090
0.00 (0.00%)
Sep 18, 2026, 1:47 PM AEST
Anatara Lifesciences Revenue
In the fiscal year ending June 30, 2026, Anatara Lifesciences had annual revenue of 318.40K AUD, down -67.16%. Anatara Lifesciences had revenue of 140.84K in the half year ending June 30, 2026, a decrease of -62.07%.
Revenue
318.40K
Revenue Growth
-67.16%
P/S Ratio
8.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.84M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 318.40K | -651.05K | -67.16% |
| Jun 30, 2025 | 969.46K | 325.43K | 50.53% |
| Jun 30, 2024 | 644.03K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Bio-Gene Technology | 1.08M |
| Nexalis Therapeutics | 1.07M |
| Biotron | 525.87K |
| ReNerve | 510.36K |